Purisys
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Purisys - overview
Established
2019
Location
Athens, GA-Georgia, US
Primary Industry
Pharmaceuticals
About
Purisys, based in the US, specializes in the development and manufacturing of custom Active Pharmaceutical Ingredients (APIs), supporting pharmaceutical companies from pre-clinical research to commercialization. Purisys focuses on custom Active Pharmaceutical Ingredients (APIs) and other chemical synthesis projects. Founded in 2019 in Athens, US, the company has executed 2 deals, with the most recent on January 27, 2026. No changes in business strategy or ownership have been reported.
Purisys specializes in the development and manufacturing of custom Active Pharmaceutical Ingredients (APIs) and chemical synthesis projects, providing support from pre-clinical research to full-scale commercialization. Their services include custom API development, primarily in cannabinoid and psychedelic chemistry, catering to both emerging biotech firms and established pharmaceutical companies. The company produces all major cannabinoids and various related substances necessary for research and regulatory compliance in clinical trials. Purisys complies with Good Manufacturing Practices (GMP) and FDA regulations, ensuring product safety and efficacy for clients across North America, Europe, and other regions.
Purisys generates revenue through business-to-business contracts for development and manufacturing services tailored to client needs. They engage with pharmaceutical and biotech firms for process development, analytical capabilities, and small-scale manufacturing. Revenue is supported by a catalog of over 300 commercial reference standards, which clients use for development and regulatory compliance, although specific pricing details are undisclosed. Purisys plans to leverage its recent acquisition by Siegfried Holding AG, which will enhance its capabilities and market presence.
The acquisition is set to be finalized on January 27, 2026. The company is targeting expansion into emerging markets, although specific regions have not been mentioned. This strategic move aims to bolster their product offerings and support future growth initiatives.
Current Investors
SK Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.purisys.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Purisys - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Purisys LLC | - | ||||||||
| Spin-Off | Completed | Purisys LLC | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.